Search results
Results From The WOW.Com Content Network
Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and Andrew Perlman, [1] and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, [2] the company was ...
J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, [2] and Morges, Switzerland. [3] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 [4] and Incyte Genomics, Inc. of Delaware. [5]
After Actelion was bought by Johnson & Johnson in 2017, [1] Idorsia was spun out into a new company and started operating on the same campus where Actelion was founded under the leadership of Actelion founders Jean-Paul Clozel as CEO and Martine Clozel as CSO.
Scrip World Pharmaceutical News was initially published by advertising company J Walter Thomson but was bought by Dr Philip J Brown in 1976 for £2000, who founded PJB Publishing. Brown sold Scrip, associated titles, and his company to Informa for £150 million in 2003.
Regulatory developments, FDA/EMEA news, market legislation, pharma market movements, reviews of current and proposed legislation and regulation, conference details, and write-ups. Barbara Obstoj is the Managing Editor, which in 2009 acquired the archives of The Pharma Marketletter, a publication Barbara owned since 1991 and prior to that edited ...
Mylan Pharmaceuticals was founded as a drug distributor in 1961 by Milan Puskar and Don Panoz. [12] In 1966, the company began manufacturing penicillin G tablets as well as vitamins and other dietary supplements.
Quark Pharmaceutical signed a collaboration agreement with the University of Michigan for the development of proprietary SiRNA for noise-induced hearing loss. The collaboration includes studies on different SiRNA candidate drugs inhibiting Quark's proprietary target genes for the prevention and treatment of hearing loss caused by acoustic trauma.